RU93058374A - ANTIVIRAL AGENT - Google Patents

ANTIVIRAL AGENT

Info

Publication number
RU93058374A
RU93058374A RU93058374/14A RU93058374A RU93058374A RU 93058374 A RU93058374 A RU 93058374A RU 93058374/14 A RU93058374/14 A RU 93058374/14A RU 93058374 A RU93058374 A RU 93058374A RU 93058374 A RU93058374 A RU 93058374A
Authority
RU
Russia
Prior art keywords
treatment
antiviral agent
riboflavin
vitamin
diseases associated
Prior art date
Application number
RU93058374/14A
Other languages
Russian (ru)
Inventor
Берк Жан
Original Assignee
Берк Жан
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Берк Жан filed Critical Берк Жан
Publication of RU93058374A publication Critical patent/RU93058374A/en

Links

Claims (1)

Изобретение относится к новому применению рибофлавина или витамина В2 для лечения болезней, связанных с вирусами HIV, в лечении герпеса, пигментарного ретинита и малярии. Рибофлавин может соединяться с витамином РР или AZT в лечении болезней, связанных с вирусами HIV. Клинические испытания показывают ремиссию симптомов герпеса и улучшение состояния пациентов, пораженных СПИДом.The invention relates to a new use of riboflavin or vitamin B2 for the treatment of diseases associated with HIV viruses in the treatment of herpes, retinitis pigmentosa and malaria. Riboflavin can combine with vitamin PP or AZT in the treatment of diseases associated with HIV viruses. Clinical trials show remission of herpes symptoms and an improvement in the condition of AIDS-infected patients.
RU93058374/14A 1991-04-02 1992-04-02 ANTIVIRAL AGENT RU93058374A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9104218 1991-04-02

Publications (1)

Publication Number Publication Date
RU93058374A true RU93058374A (en) 1996-10-10

Family

ID=

Similar Documents

Publication Publication Date Title
CA2033044A1 (en) 6-substituted purine carbocyclic nucleosides
CA2105487A1 (en) Antiviral nucleoside combination
EP0349242A3 (en) Therapeutic nucleosides
RU93045710A (en) ANTIVIRAL NUCLEOSIDE COMPOSITION, METHOD OF ITS PRODUCTION AND METHOD OF TREATMENT
CA2012125A1 (en) Use of functional derivatives of the intercellular adhesion molecule icam-1 in anti-viral therapy
EP0293826A3 (en) Therapeutic and prophylactic application of sulfated polysaccharides against aids
ATE100098T1 (en) NUCLEOSIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS.
EP0273277A3 (en) Pharmaceutical composition comprising 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) in treating patients infected with retrovirus
WO1992017173A3 (en) Use of riboflavin for treating hiv-related diseases, herpes, retinitis pigmentosa and malaria
BE1000722A4 (en) PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDES ADAPTED TO GASTROINTESTINAL RESORPTION.
CA2120743A1 (en) Antiviral acyclic phosphonomethoxyalkyl substituted, alkenyl and alkynyl purine and pyrimidine derivatives
IE892565L (en) Heparin fragments and fractions with anti-hiv action
Dalakas et al. Treatment of human immunodeficiency virus—related polyneuropathy with 3′‐azido‐2′, 3′‐dideoxythymidine
NO970847D0 (en) 2- [Amino-6- (cyclopropylamino) -9H-purin-9-yl] -2-cyclopenten-1-methanol succinate as anti-viral agent
IE892654L (en) Therapeutic nucleosides
RU93058374A (en) ANTIVIRAL AGENT
EP0311107A3 (en) Anti-hiv active 3'-fluoro-purine-2',3'-dideoxyribosides
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
MC1930A1 (en) ANTIVIRAL PRODUCT
AU3852989A (en) Method of inhibiting the activity of human immunodeficiency virus (hiv) in vivo
CA2285463A1 (en) A combination therapy for hiv infections
EP0311108A3 (en) Anti-hiv active 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside
JPS6438030A (en) Preventing and treating agent for aids
James Saquinavir: major study shows survival benefit in treatment-naive patients
GB9108085D0 (en) Complexes of polyadenylic acid with polyuridylic acid